Olympus Secures Global Distribution Rights for Endocision Cryosystem
Olympus Corporation has finalized an exclusive global distribution agreement with Canadian firm Endocision to market a portable, single-use flexible cryocatheter system. The partnership aims to integrate Endocision’s specialized cryotechnology into Olympus’ existing respiratory portfolio, with a commercial rollout slated for the U.S., Canada, and Europe by early 2026.

The new system distinguishes itself through a portable design that eliminates the need for bulky CO2 tanks or external power sources. This allows clinicians to perform cryobiopsies and airway interventions across diverse hospital environments, including intensive care units, emergency departments, and standard operating rooms. By facilitating procedures such as tissue acquisition, foreign body removal, and tumor debulking, the device provides a versatile alternative to conventional forceps biopsies, which are often limited by tissue compression damage.
Seiji Kuramoto, head of the Surgical and Interventional Solutions Division at Olympus, noted that the collaboration pairs Olympus’ established ultrasound expertise with Endocision’s cryotechnology to improve diagnostic accuracy. Dr. Moishe Liberman, CEO of Endocision, emphasized that the system is engineered for compatibility with both traditional and robotic bronchoscopy platforms. The companies will debut the hardware at the American Association for Bronchology and Interventional Pulmonology annual conference in Denver this August.
Comments (0)
No comments yet. Be the first!